PMID- 20547193
OWN - NLM
STAT- MEDLINE
DCOM- 20110131
LR  - 20151119
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 71
IP  - 9
DP  - 2010 Sep
TI  - Upregulation of human leukocyte antigen-G expression and its clinical 
      significance in ductal breast cancer.
PG  - 892-8
LID - 10.1016/j.humimm.2010.06.009 [doi]
AB  - Human leukocyte antigen(HLA)-G could inhibit functions of immune cells and induce 
      regulatory T cells (Treg) and could be involved in antitumor immune responses. In 
      the current study, HLA-G expression in 58 primary breast cancer lesions was 
      analyzed with immunohistochemistry. Plasma soluble HLA-G was detected with 
      enzyme-linked immunosorbent assay in 92 breast cancer patients and in 70 normal 
      healthy donors. The proportion of CD4(+)CD25(+)FoxP3(+) Treg was analyzed with 
      flow cytometry in 64 breast cancer patients and 23 normal controls. HLA-G 
      expression was observed in 70.7% (41/58) of breast cancer lesions. Lesion HLA-G 
      expression was more frequently observed in advanced disease stage (I/II vs 
      III/IV, p = 0.044) and tumor grade (I/II vs III/IV, p = 0.021). sHLA-G was 
      dramatically increased in patients when compared with normal controls (median 
      82.19 vs 9.65 U/ml, p < 0.001); The area under the receiver operating 
      characteristic (ROC) curve for sHLA-G was 0.953 (95% confidence interval [CI] = 
      0.926-0.981, p < 0.001). However, sHLA-G was irrelevant to the disease stage and 
      tumor grade. Moreover, CD4(+)CD25(+)FoxP3(+) Treg are markedly increased in the 
      breast cancer patients compared with normal controls (4.46+/-1.36% vs 
      2.67+/-1.45%, p < 0.001), and the increased frequency of Treg was strongly 
      correlated to sHLA-G levels (R = 0.582, p = 0.001). Our findings indicated that 
      HLA-G could play critical roles in the progression of breast cancer, and plasma 
      sHLA-G levels might be a useful preoperative biomarker for diagnosis.
CI  - Copyright 2010 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Chen, Hai-Xiao
AU  - Chen HX
AD  - Human Tissue Bank, Taizhou Hospital of Zhejiang Province, Wenzhou Medical 
      College, Linhai, Zhejiang, China.
FAU - Lin, Aifen
AU  - Lin A
FAU - Shen, Chao-Jun
AU  - Shen CJ
FAU - Zhen, Rui
AU  - Zhen R
FAU - Chen, Bao-Guo
AU  - Chen BG
FAU - Zhang, Xia
AU  - Zhang X
FAU - Cao, Fei-Ling
AU  - Cao FL
FAU - Zhang, Jian-Gang
AU  - Zhang JG
FAU - Yan, Wei-Hua
AU  - Yan WH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100612
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Biomarkers)
RN  - 0 (FOXP3 protein, human)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Breast Neoplasms/blood/diagnosis/immunology/*metabolism/pathology
MH  - Carcinoma, Ductal/blood/diagnosis/immunology/*metabolism/pathology
MH  - Cell Count
MH  - Cell Membrane/metabolism
MH  - Cytoplasm/metabolism
MH  - Female
MH  - Forkhead Transcription Factors/metabolism
MH  - HLA Antigens/blood/immunology/*metabolism
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/blood/immunology/*metabolism
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - ROC Curve
MH  - Sensitivity and Specificity
MH  - T-Lymphocytes, Regulatory/metabolism/pathology
MH  - *Up-Regulation
EDAT- 2010/06/16 06:00
MHDA- 2011/02/01 06:00
CRDT- 2010/06/16 06:00
PHST- 2010/04/08 00:00 [received]
PHST- 2010/06/01 00:00 [revised]
PHST- 2010/06/04 00:00 [accepted]
PHST- 2010/06/16 06:00 [entrez]
PHST- 2010/06/16 06:00 [pubmed]
PHST- 2011/02/01 06:00 [medline]
AID - S0198-8859(10)00152-7 [pii]
AID - 10.1016/j.humimm.2010.06.009 [doi]
PST - ppublish
SO  - Hum Immunol. 2010 Sep;71(9):892-8. doi: 10.1016/j.humimm.2010.06.009. Epub 2010 
      Jun 12.